Roche Commitment to HIVAIDS in Africa

1
Roche Commitment to HIV/AIDS in Africa

• Christopher MurrayHead of Pharma International
  Roche

2
Roche commitment to HIV/AIDS in Africa
Supporting AIDS Orphans in Africa
AIDS Technology Transfer Initiative
Pricing Patent Policies
Roche Pharmaceuticals in HIV/AIDS
Supporting Development of Local Healthcare Systems
Accelerating Access Initiative
3
Roche Pharmaceuticals in HIV/AIDS

• Relatively small player globally
• Represent lt5 share of global antiretroviral
  market
• 2 HIV protease inhibitor medicines recommended in
  WHO treatment guidelines for resource limited
  settings
• Invirase (saquinavir)
• Viracept (nelfinavir) in specific patient
  populations

4
HIV Protease Inhibitor pricing policy

• Focuses on countries with fewest resources and
  greatest need
• No profit prices for Invirase and Viracept for
  sub-Saharan Africa
• Includes Viracept paediatric formulation
• Will include Invirase 500 upon local
  registrations
• Roche no profit priceslower than generic copies

MSF June 05
5
Roche patent policies

• No patents on new antiretroviral medicines in
  sub-Saharan Africa
• Enabling generic production
• No need for voluntary or compulsory licences
• No action in these countries against generic
  versions of antiretroviral medicines for which
  Roche holds patents

6
Applying Roche policies
7Standard prices
93Reduced prices

• Patents and profit both removed as barriers for
  gt 26 million people living with HIV/AIDS
• 69 of all people living with HIV/AIDS
  worldwide
• Reduced pricing applies for 93 of all people
  living with HIV/AIDS
• Standard prices apply to 7 of global patient
  population

69No profit, no patent policies

• from UNAIDS country data, July 2005

7
Report available English and French
8
Roche drug donations policy

• Drug donations are not a key component of our
  policies to increase sustainable access to Roche
  medicines
• Donating drug for chronic diseases such as
  HIV/AIDS is totally different to donating
  emergency aid (e.g. tsunami)
• Ethics
• We believe it to be unethical to donate HIV
  medicines with no guarantee of continuous
  lifelong supply for each recipient

9
New Technology Transfer Initiative

• Africa expected to be worlds biggest user of
  ARVs
• Aims
• Use Roche knowledge to strengthen manufacturing
  capability in Africa
• Provide local manufacturers with technical
  expertise required to produce generic HIV
  medicine
• Model based upon processes to manufacture
  saquinavir (now recommended by WHO as a 2nd line
  treatment)
• Full team fully operational from Q2 2006
• Team based part in Africa, part at Roche HQ,
  Switzerland

10
Technology Transfer InitiativeProgress to date

• Within 2 months of announcement, 16 companies
  from 9 eligible countries expressed interest
• (94 of companies from sub-Saharan Africa)

11
Accelerating Access Initiative (AAI)

• Public Private Partnership established in 2000
  between 7 companies and 5 UN agencies
• Abbott, BMS, BI, GSK, Merck, Gilead, Roche
  together with WHO, UNAIDS, World Bank, UNICEF,
  UNFPA
• By end 2005, more than 716,000 people living with
  HIV/AIDS in developing countries were receiving
  treatment, with at least one ARV medicine
  provided by AAI companies
• In Africa, over 446,000 patients are being
  treated with medicine supplied by AAI companies
• 116 increase over 2004 is a 45-fold increase in
  number of people treated with ARV supplied by AAI
  companies in Africa since establishment of AAI

12
Supporting the development of local healthcare
systems

• Programmes implemented in partnership in
  developing countries include
• CARE with PharmAccess
• Delivered training to hundreds of healthcare
  professionals from over 16 African countries
• Materials available on DVD and www.roche-hiv.com
• Cambodian Treatment Access Programme with UNSW
• CARE learnings have enabled a more rapid scale-up
  of treatment now large-scale funding is available
• Key sustainable contribution is delivery of HIV
  education and training for local healthcare
  professionals

13
Supporting AIDS orphans in AfricaRoche engaged
on individual company level

• What?
• Annual employee fund-raising initiative to
  support orphans in Malawi
• Roche matches funds raised
• Why?
• Partnership with ECPP to manage 7 centres serving
  3000 orphans
• Provide children with food, water, shelter,
  education skill development
• Achievement to date
• In 2004 over 8,000 employees from 59 sites
  participated in Roche Global Employee AIDS Walk
  raising 1,500,000 Swiss Francs
• 50 growth in participation in 2005 12,000
  employees across 85 sites committed to help the
  orphans

14
In Africa and LDCs, HIV/AIDS is not business as
usual for Roche

• Access to healthcare and medicines will always be
  an issue when half the planet live on lt2 per
  day
• Each day we strive to achieve a sustainable
  balance between innovation and access, compassion
  and commerce